Study to assess the effect of Ticagrelor on coronary blood flow in healthy male subjects.
Study identifier:D5130C00067
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2010-021820-91
CTIS identifier:N/A
Study Complete
Official Title
A randomized, double-blind, placebo controlled, crossover, single centre phase I study to assess the effect of Ticagrelor on adenosine-induced coronary blood flow velocity in healthy male subjects
Medical condition
blood flow speed
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD6140, Placebo
Sex
Male
Actual Enrollment
39
Study type
Interventional
Age
18 Years - 40 Years
Date
Study Start Date: 01 Dec 2010
Primary Completion Date: 01 Apr 2011
Study Completion Date: 01 Apr 2011
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder | Drug: AZD6140 P2Y12 receptor antagonist Other Name: Ticagrelor |
| Placebo Comparator: 2 Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder | - |
Contacts
Investigators
Principal Investigator
Jay Horrow
AstraZeneca
